Latest Commercialization News

Rhythm Biosciences has completed critical validation of its ColoSTAT colorectal cancer assay and submitted it for ISO15189 accreditation, paving the way for commercialisation. The test demonstrated strong clinical performance, highlighting its potential as a non-invasive diagnostic tool.

Integrated Research reported steady pro-forma revenue in FY25 despite declines in statutory revenue and profits, driven by a softer renewals book and market uncertainty. The company’s product-led growth strategy gained momentum with new product launches and a major contract renewal.

EMVision Medical Devices is set to activate its sixth and final pivotal trial site at UCLA Health, advancing its emu™ brain scanner towards FDA submission. Meanwhile, the Continuous Innovation Study grows with the addition of Box Hill Hospital.

Omega Oil and Gas confirms the commercial viability of its Canyon Sandstone reservoir in Queensland’s Taroom Trough, with SLB modelling indicating nearly 1 million barrels of oil equivalent per well and significant upside potential.

IperionX secures a $12.5 million funding tranche from the U.S. Department of Defense to fast-track expansion of its Virginia titanium manufacturing capacity beyond 1,000 metric tons annually.

Big River Industries reported a 2.3% revenue decline for FY25 amid tough market conditions but achieved a notable rebound in the second half, driven by operational efficiencies and cost controls. The company maintains a strong balance sheet and a cautiously optimistic outlook for FY26.

Big River Industries reported a modest revenue decline in FY25 but achieved improved margins and operational efficiencies in the second half, positioning itself for growth as market conditions begin to stabilise.

Big River Industries reported a statutory net loss of $14.7 million for FY2025, driven by a $20 million impairment charge on intangible assets amid a 2.3% revenue decline. Despite the setback, the company declared a fully franked 2 cent dividend and showed signs of operational stabilization.

Johns Lyng Group reported a modest 1.8% revenue increase for FY25, driven by strong business-as-usual growth despite a steep decline in catastrophe-related income. The company’s FY26 forecast anticipates continued revenue expansion amid ongoing operational challenges.

Bio-Gene Technology Limited reported a net loss of AUD 2.58 million for FY2025 while making significant strides in developing its bio-insecticides Flavocide and Qcide, securing US Department of Defense grants and expanding global partnerships.

SPC Global reports stronger-than-expected FY25 results driven by international growth and synergy gains, while unveiling a new premium beverage division and a major lender transition.

Johns Lyng Group delivered steady FY25 financial results with revenue growth and strong core operations, while securing a $1.1 billion acquisition offer from Pacific Equity Partners.